Rate and Predictors of Bacteremia in Afebrile Community-Acquired Pneumonia.


Journal

Chest
ISSN: 1931-3543
Titre abrégé: Chest
Pays: United States
ID NLM: 0231335

Informations de publication

Date de publication:
03 2020
Historique:
received: 28 04 2019
revised: 03 09 2019
accepted: 04 10 2019
pubmed: 2 11 2019
medline: 21 10 2020
entrez: 1 11 2019
Statut: ppublish

Résumé

Although blood cultures (BCs) are the "gold standard" for detecting bacteremia, the utility of BCs in patients with community-acquired pneumonia (CAP) is controversial. This study describes the proportion of patients with CAP and afebrile bacteremia and identifies the clinical characteristics predicting the necessity for BCs in patients who are afebrile. Bacteremia rates were determined in 4,349 patients with CAP enrolled in the multinational cohort study The Competence Network of Community-Acquired Pneumonia (CAPNETZ) and stratified by presence of fever at first patient contact. Independent predictors of bacteremia in patients who were afebrile were determined using logistic regression analysis. Bacteremic pneumonia was present in 190 of 2,116 patients who were febrile (8.9%), 101 of 2,149 patients who were afebrile (4.7%), and one of 23 patients with hypothermia (4.3%). Bacteremia rates increased with the CURB-65 score from 3.5% in patients with CURB-65 score of 0 to 17.1% in patients with CURB-65 score of 4. Patients with afebrile bacteremia exhibited the highest 28-day mortality rate (9.9%). Positive pneumococcal urinary antigen test (adjusted OR [AOR], 4.6; 95% CI, 2.6-8.2), C-reactive protein level > 200 mg/L (AOR, 3.1; 95% CI, 1.9-5.2), and BUN level ≥ 30 mg/dL (AOR, 3.1; 95% CI, 1.9-5.3) were independent positive predictors, and antibiotic pretreatment (AOR, 0.3; 95% CI, 0.1-0.6) was an independent negative predictor of bacteremia in patients who were afebrile. A relevant proportion of patients with bacteremic CAP was afebrile. These patients had an increased mortality rate compared with patients with febrile bacteremia or nonbacteremic pneumonia. Therefore, the relevance of fever as an indicator for BC necessity merits reconsideration.

Sections du résumé

BACKGROUND
Although blood cultures (BCs) are the "gold standard" for detecting bacteremia, the utility of BCs in patients with community-acquired pneumonia (CAP) is controversial. This study describes the proportion of patients with CAP and afebrile bacteremia and identifies the clinical characteristics predicting the necessity for BCs in patients who are afebrile.
METHODS
Bacteremia rates were determined in 4,349 patients with CAP enrolled in the multinational cohort study The Competence Network of Community-Acquired Pneumonia (CAPNETZ) and stratified by presence of fever at first patient contact. Independent predictors of bacteremia in patients who were afebrile were determined using logistic regression analysis.
RESULTS
Bacteremic pneumonia was present in 190 of 2,116 patients who were febrile (8.9%), 101 of 2,149 patients who were afebrile (4.7%), and one of 23 patients with hypothermia (4.3%). Bacteremia rates increased with the CURB-65 score from 3.5% in patients with CURB-65 score of 0 to 17.1% in patients with CURB-65 score of 4. Patients with afebrile bacteremia exhibited the highest 28-day mortality rate (9.9%). Positive pneumococcal urinary antigen test (adjusted OR [AOR], 4.6; 95% CI, 2.6-8.2), C-reactive protein level > 200 mg/L (AOR, 3.1; 95% CI, 1.9-5.2), and BUN level ≥ 30 mg/dL (AOR, 3.1; 95% CI, 1.9-5.3) were independent positive predictors, and antibiotic pretreatment (AOR, 0.3; 95% CI, 0.1-0.6) was an independent negative predictor of bacteremia in patients who were afebrile.
CONCLUSIONS
A relevant proportion of patients with bacteremic CAP was afebrile. These patients had an increased mortality rate compared with patients with febrile bacteremia or nonbacteremic pneumonia. Therefore, the relevance of fever as an indicator for BC necessity merits reconsideration.

Identifiants

pubmed: 31669433
pii: S0012-3692(19)34102-9
doi: 10.1016/j.chest.2019.10.006
pii:
doi:

Substances chimiques

Polysaccharides, Bacterial 0
polysaccharide C-substance (Streptococcus) 0
C-Reactive Protein 9007-41-4

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

529-539

Investigateurs

M Dreher (M)
C Cornelissen (C)
W Knüppel (W)
D Stolz (D)
N Suttorp (N)
M Witzenrath (M)
P Creutz (P)
A Mikolajewska (A)
T Bauer (T)
D Krieger (D)
W Pankow (W)
D Thiemig (D)
B Hauptmeier (B)
S Ewig (S)
D Wehde (D)
M Prediger (M)
S Schmager (S)
M Kolditz (M)
B Schulte-Hubbert (B)
S Langner (S)
W Albrich (W)
T Welte (T)
J Freise (J)
G Barten (G)
O Arenas Toro (O)
M Nawrocki (M)
J Naim (J)
M Witte (M)
W Kröner (W)
T Illig (T)
N Klopp (N)
M Kreuter (M)
F Herth (F)
S Hummler (S)
P Ravn (P)
A Vestergaard-Jensen (A)
G Baunbaek-Knudsen (G)
M Pletz (M)
C Kroegel (C)
J Frosinski (J)
J Winning (J)
B Schleenvoigt (B)
K Dalhoff (K)
J Rupp (J)
R Hörster (R)
D Drömann (D)
G Rohde (G)
J Drijkoningen (J)
D Braeken (D)
H Buschmann (H)
T Schaberg (T)
I Hering (I)
M Panning (M)
M Wallner (M)

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2019 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

Auteurs

Christina Forstner (C)

Institute of Infectious Diseases and Infection Control, University Hospital, Jena, Germany; Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria. Electronic address: christina.forstner@med.uni-jena.de.

Vladimir Patchev (V)

Institute of Infectious Diseases and Infection Control, University Hospital, Jena, Germany.

Gernot Rohde (G)

Medical Department I, Department of Respiratory Medicine, Goethe University Hospital, Frankfurt/Main, Germany; Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Member of the German Center for Lung Research (DZL); CAPNETZ Stiftung, Hannover, Germany.

Jan Rupp (J)

CAPNETZ Stiftung, Hannover, Germany; Department of Infectious Diseases and Microbiology, University Hospital Schleswig-Holstein, Lübeck, Germany; German Center for Infection Research (DZIF), partner site Hamburg-Lübeck-Borstel-Riems, Lübeck, Germany.

Martin Witzenrath (M)

CAPNETZ Stiftung, Hannover, Germany; Department of Infectious Diseases and Pulmonary Medicine and the Division of Pulmonary Inflammation, Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

Tobias Welte (T)

Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Member of the German Center for Lung Research (DZL); CAPNETZ Stiftung, Hannover, Germany; Department of Pneumology, Hannover Medical School, Hannover, Germany.

Heinz Burgmann (H)

Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria.

Mathias W Pletz (MW)

Institute of Infectious Diseases and Infection Control, University Hospital, Jena, Germany; CAPNETZ Stiftung, Hannover, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH